Product Pathways - Vesicle Trafficking
REPS1 (D6F4) Rabbit mAb #6404
|6404S||100 µl (10 western blots)||---||In Stock||---|
|6404||carrier free and custom formulation / quantity||email request|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
REPS1 (D6F4) Rabbit mAb recognizes endogenous levels of total REPS1 protein.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asn189 of human REPS1 protein.
REPS1 is a RalBP1-associated EH-homology domain containing protein. The sequence of REPS1 has an EH domain, followed by two proline-rich segments, and a C-terminal coiled-coil domain for binding to RalBP1 (1). The EH domain of REPS1 interacts with the NPF motif of Rab11-FIP2, mediates their colocalization to endosome vesicles, and influences EGFR endocytosis (2). The two proline-rich regions of REPS1 are important for binding to the SH3 domain of GRK/GRB2 and further regulate EGFR downstream signaling. The proline-rich regions of REPS1 have also been shown to interact with the SH3 domain of intersectin1 (ITSN1) and contribute to ITSN1/SGIP1/REPS1 complex formation on clathrin-coated pits (3). Three alternatively spliced isoforms of REPS1 have been identified.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7727 Biotinylated Protein Ladder Detection Pack
- 12005 Phospho-REPS1 (Ser709) (D8C1) Rabbit mAb
- 6884 Phospho-REPS1 (Ser709) Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 6883 SignalFire™ ECL Reagent
- 12757 SignalFire™ Elite ECL Reagent
- 12630 SignalFire™ Plus ECL Reagent
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.